| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE38115 | AVANIR PHARMS | Dextromethorphan and an oxidase inhibitor for treating intractable conditions |
Jan, 2016
(8 years ago) | |
| US8227484 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Jul, 2023
(9 months ago) | |
| US7659282 | AVANIR PHARMS | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
Aug, 2026
(2 years from now) | |
Nuedexta is owned by Avanir Pharms.
Nuedexta contains Dextromethorphan Hydrobromide; Quinidine Sulfate.
Nuedexta has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Nuedexta are:
- USRE38115
- US8227484
Nuedexta was authorised for market use on 29 October, 2010.
Nuedexta is available in capsule;oral dosage forms.
Nuedexta can be used as treatment of pseudobulbar affect.
The generics of Nuedexta are possible to be released after 13 August, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | Oct 29, 2013 |
Drugs and Companies using DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE ingredient
Market Authorisation Date: 29 October, 2010
Treatment: Treatment of pseudobulbar affect
Dosage: CAPSULE;ORAL
How can I launch a generic of NUEDEXTA before it's drug patent expiration?
More Information on Dosage
NUEDEXTA family patents
